Marinus Pharmaceuticals, Inc. (MRNS)

1,5100 +0,0600 (+4,14%) Börsenschluss: 04:00PM EDT

Marinus Pharmaceuticals, Inc.

5 Radnor Corporate Center
Suite 500 100 Matsonford Road
Radnor, PA 19087
United States
484 801 4670
https://marinuspharma.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 165

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Scott N. Braunstein M.D.	CEO, President & Chairman	1,01M	N/A	1963
Mr. Steven E. Pfanstiel C.M.A., M.B.A.	COO, CFO & Treasurer	670,25k	N/A	1973
Dr. Joseph Hulihan M.D.	Chief Medical Officer	665,47k	N/A	1957
Dr. Alex Aimetti Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Ms. Sonya Weigle	Senior VP of Investor Relations, Human Resources & Corporate Affairs	N/A	N/A	N/A
Ms. Martha E. Manning Esq., J. D.	Senior VP, General Counsel & Secretary	N/A	N/A	1955
Molly Cameron	Director of Corporate Communications & Investor Relations	N/A	N/A	N/A
Dr. Kimberly A. McCormick Pharm.D.	Chief Regulatory & Quality Assurance Officer	N/A	N/A	N/A
Mr. Thomas J. Lyons	Chief Business Officer	N/A	N/A	N/A
Ms. Christina Shafer	Chief Commercial Officer	N/A	N/A	1977

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

Corporate Governance

Marinus Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 7. Die grundlegenden Scores sind Audit: 6, Vorstand: 7, Shareholderrechte: 6, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.